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Abstract
Background: Coagulation abnormalities are involved in the pathogenesis of acute exacerbations of idiopathic
pulmonary fibrosis (AE-IPF). The administration of recombinant human soluble thrombomodulin (rhTM), which
has both anti-inflammatory and anticoagulant activities, improves outcomes and respiratory function in patients
with acute respiratory distress syndrome. Therefore, we conducted a prospective clinical study to examine the
effects of rhTM on respiratory function, coagulation markers, and outcomes for patients with AE-IPF.
Methods: After registration of the protocol, the patients with AE-IPF who satisfied the study inclusion criteria were
treated daily with 380 U/kg of rhTM for 7 days and steroid pulse therapy. The concomitant administration of
immunosuppressants and polymyxin B-immobilized fiber column treatment was prohibited. The sample size
was 10 subjects. The primary study outcome was the improvement of PaO2/FiO2 ratio a week after treatment
initiation. Secondary outcomes were change in D-dimer level over time and 28-day survival rate in patients
without intubation. Study data were compared with historical untreated comparison group, including 13 patients
with AE-IPF who were treated without rhTM before the registration.
Results: The mean PaO2/FiO2 ratio for the rhTM treatment group (n = 10) on day 8 significantly improved
compared with that on day one (two-way analysis of variance, p = 0.01). The mean D-dimer level tended to
decrease in the rhTM group on day 8, but the change was not significant. The 28-day survival rate was 50 %
higher in the rhTM group than in the historical untreated comparison group, but the difference was not
significant. A post hoc analysis showed that overall survival time was significantly longer in the treated group
compared with that of the historical untreated comparison group (p = 0.04, log-rank test).
Conclusion: rhTM plus steroid pulse therapy improves respiratory functions in patients with AE-IPF and is
expected to improve overall patient survival without using other combination therapies.
Trial registration: The study was registered with University Hospital Medical Information Network Clinical Trial
Registry (UMIN-CTR) in October 2012 (UMIN000009082).
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Background
In patients with idiopathic pulmonary fibrosis (IPF), ab-
normal deposition of fibrin is found in the lung alveolar
spaces [1], along with strong lung tissue expression of
tissue factor, an initiator of blood coagulation, and plas-
minogen activator inhibitor-1 (PAI-1), an inhibitor of
the fibrinolytic system [2]. Gunther et al. reported that
the inhalation of heparin or urokinase suppresses the
development of bleomycin-induced pneumonitis in rab-
bits [3], and Izuhara et al. reported that a PAI-1 inhibi-
tor suppresses the development of bleomycin-induced
pneumonitis in mice [4]. These findings suggested that
anticoagulants can effectively treat IPF, but the efficacy
of warfarin was not demonstrated when given to patients
in the chronic phase of IPF [5].
Although IPF progression is usually gradual, acute ex-
acerbation of IPF (AE-IPF) can also occur. Retrospective
reviews have demonstrated that AE-IPF develops in
9.6 % of patients with IPF within 2 years of disease onset
and that these patients have an extremely poor 3-month
survival, which was found to be 40 % [6, 7]. Increased
concentrations of circulating coagulation markers are
also clinically observed in patients with AE-IPF [8]. Kubo
et al. reported that the administration of low-molecular
weight heparin improved the AE-IPF outcomes compared
with those of untreated controls [9], but no subsequent
reports have supported this finding.
Thrombomodulin is a membranous protein found on
the surface of vascular endothelial cells. It directly inhibits
clotting activity through the formation of a complex
with thrombin and further suppresses blood coagulation
through its activation of protein C. Thrombomodulin has
anti-inflammatory as well as high mobility group box 1
(HMGB1) inhibitory and anticoagulant activities [10, 11].
Recombinant human soluble thrombomodulin (rhTM)
demonstrates anticoagulation effects superior to hep-
arin for the treatment of disseminated intravascular
coagulation (DIC) [12] and improves the outcomes and
respiratory functions in patients with sepsis-induced
acute respiratory distress syndrome (ARDS) [13]. Fur-
thermore, Ebina et al. reported reduced expression of
thrombomodulin on the surface of vascular endothelial
cells in autopsy cases of AE-IPF [14]. Based on these
findings, we conducted a clinical study to examine the
efficacy of rhTM treatment of AE-IPF.
Methods
Patients treated with rhTM
The study protocol was registered with the University Hos-
pital Medical Information Network Clinical Trial Registry
(UMIN-CTR) in October 10, 2012 (UMIN000009082).
The study was a single center, single arm, non-randomized,
prospective clinical trial, though we used the historical
untreated comparison group. After registration, the patients
who met all the following conditions were enrolled in
this study: patients over 20 years old who were hospi-
talized in Sakura hospital, Toho-university medical center
with a diagnosis of AE-IPF based on the diagnostic cri-
teria, those who did not meet the exclusion criteria, and
those who provided written informed consent.
The authors confirm that all related trials for this
drug are registered. No incentives were presented for
recruitment of the partecipants.
IPF and AE-IPF diagnostic criteria
IPF was diagnosed according to the criteria of the
American Thoracic Society/European Respiratory Society/
Japanese Respiratory Society/Latin American Thoracic
Association statement for IPF [15]. After the exclusion
of pulmonary fibrosis due to collagen disease, professional
exposure, hypersensitivity pneumonitis, and drug-induced
lung disease, high-resolution computed tomography (CT;
HRCT) images were evaluated by more than one respira-
tory specialist and experienced radiologists to confirm the
usual interstitial pneumonia (UIP) pattern. Surgical biopsy
was not performed.
AE-IPF was diagnosed according to the following
criteria [6]: previous or concurrent IPF diagnosis; un-
predicted acute worsening of dyspnea within 30 days;
development of new ground-glass opacity or consolida-
tion; and exclusion of pulmonary infection, left heart
failure, pulmonary embolism, and acute lung injury from
an already identified cause.
The following tests were performed to diagnose bacter-
ial and viral infections: smear and culture tests of sputum,
blood and urine that detect bacteria including acid-fast
bacteria; antigen tests for influenza virus, Mycoplasma
pneumonia, Streptococcus pneumonia, Legionella pneumo-
nia, and cytomegalovirus; antibody test for Mycoplasma
pneumonia and Chlamydia pneumonia; and assays for
procalcitonin and β-D glucan. Patients were excluded if
the possibility of infection could not be ruled out.
Exclusion criteria
The patients who met any of the following conditions
were excluded: 1) those with previous history of AE-IPF;
2) who was receiving corticosteroids or immunosuppres-
sants; 3) who was receiving anti-coagulant therapy; 4)
who had intracranial hemorrhage, pulmonary hemorrhage
and/or gastrointestinal hemorrhage; 5) those with previ-
ous history of hypersensitivity against thrombomodulin; 6)
those with active infectious disease; and 7) who was or
possibly pregnant at the time of registration.
Historical untreated comparison group
Out of 18 patients hospitalized in our department diag-
nosed as AE-IPF between April 2009 and May 2012, 13
were retrospectively assessed for eligibility based on the
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same criteria and exclusion criteria applied to the rhTM
group. These 13 patients were enrolled in this study as
“historical untreated comparison group (untreated
group)” (Fig. 1).
Medical treatment regimen
The rhTM group treatment regimen was as follows:
intravenous infusion of methylprednisolone (m-PSL) at a
dose of 1000 mg/day for 3 days (steroid pulse therapy)
and then 80 mg/day for 7 days. The necessity and dose
of steroid administration after this series was at the
attending physician’s discretion. rhTM was dissolved in
100 mL of physiological saline and intravenously in-
fused at a dose of 380 U/kg for 30 min, with initiation
immediately after the start of steroid pulse therapy.
Thereafter, rhTM was administered once a day for 7 days.
All intervention was delivered at the general ward or
intensive care unit of Toho university medical center,
Sakura hospital by the ward nursing staff.
The concomitant administration of other anticoagu-
lants, immunosuppressants, and elastase inhibitors, as well
as hemoperfusion and polymyxin B-immobilized fiber
column (PMX) treatment, was prohibited.
When oxygen saturation of 90 % could not be main-
tained with an FiO2 50 % Venturi mask, noninvasive posi-
tive pressure ventilation (NPPV) was used. For NPPV, a
BiPAP-Vision™ ventilator (Respironics Inc., Murrysville,
USA), with which FiO2 could be accurately set, was
used. However, intratracheal intubation was not actively
recommended.
In the untreated group, all patients received steroid
pulse therapy, and none was treated with rhTM. With
regard to combination therapy, no restriction was
applied in the untreated group.
Serum markers
Serum level of Krebs von der lungen-6 (KL-6) and Surfac-
tant protein D (SP-D) and HMGB1 were measured using
an electrochemical luminescence immunoassay kit (EIDIA
Co. Ltd., Tokyo, Japan; normal range < 500 U/ml), an
enzyme immunoassay kit (Yamasa Corp., Chiba, Japan;
normal range < 110 U/ml), and an enzyme-linked im-
munosorbent assay kit (Shino-test Corp., Tokyo, Japan),
respectively. D-dimer (normal range < 0.5 μg/ml) and
plasmin-α2 plasmin inhibitor complex (PIC) (normal
range < 0.8 μg/ml) levels were measured using a latex
photometric immunoassay kit (LSI Medience Corp., Tokyo,
Japan), and thrombin–antithrombin complex (TAT) was
measured using a chemiluminescent enzyme immuno-
assay kit (LSI Medience Corp., Tokyo, Japan; normal
range < 3.0 ng/ml).
Outcomes
The administration of rhTM for 1 week was reported to
improve blood gas levels in patients with acute lung in-
jury (ALI) [13]. In our historical untreated comparison
group, the arterial oxygen partial pressure (PaO2)/FiO2
(P/F) ratio was not improved at 1 week after steroid pulse
treatment. Therefore, P/F ratio improvement 1 week after
starting treatment (day 8) was used as the primary study
outcome. The P/F ratio was calculated from blood gas
levels measured in the resting supine position with oxy-
genation at a flow rate of 12 L/min and FiO2 of 50 % using
a Venturi mask. If endotracheal intubation or NPPV was
performed, blood gas was measured using the FiO2 set at
Fig. 1 Flow diagram of the patients of two groups. rhTM: recombinant human soluble thrombomodulin
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50 % and the PEEP set at 0. In the first study protocol reg-
istered with UMIN-CTR, we set the secondary outcome
as the P/F ratio on day 15 and day 29; but we excluded
them later. The mean P/F ratio of untreated group on day
15 was higher than that on day 8 that is because two se-
vere patients with poor P/F ratio had died before day 15.
Comparison between the groups in P/F ratio on day 15 or
29 were thought to be inappropriate.
D-dimer concentrations for the 13 patients in the un-
treated group did not decrease during the treatment
period (data not shown). Therefore, change in D-dimer
concentration was assessed as a secondary outcome.
Serum level of KL-6, SP-D, HMGB1, PIC and TAT were
also evaluated.
The 28-day survival rate was also used as a secondary
outcome. To avoid life extension due to intubation, the
survival period was assessed only in patients without
intubation.
Target sample size
From the data obtained in the historical untreated com-
parison group, the standard deviation of the P/F ratio in
patients with AE-IPF was presumed to be 50 to estimate
the target sample size. In addition, the effect size was also
assumed to be 1.0 for the change in the P/F ratio 1 week
after the initiation of rhTM administration. Thus, the mini-
mum target sample size was calculated to be 10 patients
with a two-sided alpha level of 0.05 and a power of 80 %.
Statistical analysis
The data were collected in Toho university medical center,
Sakura hospital, and were statistically analyzed after link-
able anonymizing of the data.
Unless otherwise noted, continuous variables were
expressed as the mean ± standard deviation. Comparisons
between two unpaired groups were performed using the
Mann–Whitney U test. Differences in the P/F ratio on days
1 and 8 between the rhTM and untreated group were eval-
uated using two-way analysis of variance (ANOVA).
Because the sphericity assumption was violated (Mauchly’s
sphericity test, p < 0.0001), we used the Greenhouse–
Geisser method. Differences in the longitudinal concentra-
tions of D-dimer, TAT, PIC and HMGB1 in the rhTM
group were tested using one-way repeated ANOVA. Differ-
ences in the study group 28-day survival rates and survival
curves were compared using the chi square and log-rank
tests, respectively. Statistical analyses were performed using
SPSS 20.0 ((IBM® SPSS® Statistics). Probability values less
than 0.05 were considered to be statistically significant.
Results
Patients' characteristics
A patient flow diagram is shown in Fig. 1. The date
range for participant recruitment was from 2012/10/30
to 2014/4/15, and follow up period was until 2014/9/30.
19 patients were assessed for eligibility, 6 patients were
excluded based on the aforementioned inclusion and
exclusion criteria. One patient refused to participate in
the study. So, rhTM administration was initiated in 11
patients. Another patient was excluded from the ana-
lysis after completion of rhTM administration, because
he was turned out to have immunodeficiency and have
pneumocystis pneumonia. Thus, the remaining 10 pa-
tients comprised the rhTM group (Fig. 1).
Table 1 shows patients' background characteristics for
the rhTM group and historical untreated comparison
group. Background characteristics of the two groups were
generally similar.
Table 2 reports baseline data obtained just before treat-
ment initiation for AE-IPF. There were no significant dif-
ferences between the two groups at this time point.
Therapeutic interventions for AE-IPF
All patients in the untreated group simultaneously received
empirical administration of antibiotics with steroid pulse
therapy, but only 4 out of the 10 patients in the rhTM
group were treated with antibiotics either before or after
rhTM administration. In the untreated group, 6, 6, and
3 patients received an elastase inhibitor (sivelestat so-
dium), an immunosuppressant (cyclosporine or cyclo-
phosphamide), and PMX treatment, respectively. One
patient received elastase inhibitors and one received im-
munosuppressants. Five patients received both. Three of







Male, n 8 11 0.8
Age 73.2 ± 9.5 69.7 ± 8.5 0.3
Pulmonary function prior to acute exacerbation





















Anticoagulant therapy 0/10 0/13
Home oxygen therapy 2/10 2/13
Data are expressed as the mean ± standard deviation
p: rhTM group vs.untreated group
rhTM recombinant human soluble thrombomodulin, FVC forced vital capacity,
IPF idiopathic pulmonary fibrosis
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these five patients received triple therapy, including
PMX. No patients in the rhTM treatment group re-
ceived these treatments.
Four out of the 13 patients in the untreated group
underwent endotracheal intubation. In the rhTM group,
1 patient required endotracheal intubation and another
patient was provided with NPPV (Table 3).
Changes in the P/F ratio 1 week after treatment initiation
The P/F ratios at the start of therapy (day 1) and on day
8 of therapy were 168 ± 56 and 215 ± 88, respectively, in
the rhTM group, and 183 ± 47 and 157 ± 55, respectively,
in the historical untreated comparison group. There was a
significant statistical interaction between group and time
point (Greenhouse–Geisser method, p = 0.005). Further
analysis of the simple main effect revealed that the mean
P/F ratio for the rhTM group on day 8 was significantly
higher than that on day 1, although it was not signifi-
cantly different from the untreated group value on day
8 (two-way ANOVA: p = 0.01 and p = 0.07, respectively)
(Table 4).
rhTM group changes in coagulation markers and HMGB1
In the rhTM group, D-dimer as well as TAT and PIC
concentrations tended to decrease, but the changes were
not statistically significant. No significant changes were
noted in HMGB1 values from the initiation of the treat-
ment to 28 days’ post-treatment (Fig. 2).
Survival rate
The survival rate for the rhTM group 28 days after the
initiation of treatment was 70 %, which was higher than
that in the historical untreated comparison group (54 %),
although the difference was not significant. A post hoc
analysis revealed that survival rates for the rhTM and
untreated groups were 70 and 23 % at 2 months, 60
and 15 % at 3 months, and 40 and 8 % at 12 months,
respectively, after treatment initiation. The median sur-
vival times for the rhTM and untreated groups were
153 and 48 days, respectively. At 1 year, the rhTM
group had a significantly better survival outcome than
the untreated group (p = 0.04 by the log-rank test) (Fig. 3).
Safety
Adverse events attributable to rhTM such as hemorrhage
were not reported.
Discussion
The present study demonstrated that combined rhTM
and steroid therapy improved the P/F ratio measured









PaO2/FiO2 ratio 168 ± 56 183 ± 47 N.A 0.5
CRP (mg/dl) 11.5 ± 8.3 11.0 ± 11.1 <0.03 0.6
LDH (IU/l) 378 ± 118 444 ± 173 120–240 0.4
KL-6 (U/ml) 1512 ± 583 2060 ± 1520 <500 0.8
SP-D (ng/ml) 482 ± 527 676 ± 711 <110 0.2
D-dimer (μg/ml) 5.3 ± 7.9 6.9 ± 8.9 <0.5 0.5
TAT (ng/ml) 8.1 ± 13.5 N.D <3.0
PIC (μg/ml) 3.0 ± 5.1 N.D <0.8
PAI-1 (ng/ml) 59.0 ± 52.4 N.D ≦50
ProteinC (%) 84.7 ± 25.1 N.D 64–135
ATIII (%) 90.9 ± 15.1 N.D 83 × 128
HMGB1 (ng/ml) 10.6 ± 4.7 N.D N.A
Thrombomodulin
(U/ml)
16.1 ± 5.9 N.D 12.1–24.9
Data are expressed as the mean ± standard deviation
p: rhTM group vs. untreated group
N.D. no data, N.A. not available
AE-IPF acute exacerbation of idiopathic pulmonary fibrosis, rhTM recombinant
human soluble thrombomodulin, CRP C-reactive protein, LDH lactate
dehydrogenase, KL-6 Krebs von der lungen-6, SP-D surfactant protein D,
TAT thrombin–antithrombin complex, PIC plasmin-α2 plasmin inhibitor
complex, PAI-1 plasminogen activator inhibitor-1, AT III antithrombin III,
HMGB1 high mobility group box 1





m-PSL pulse therapy 10/10 13/13
rhTM therapy 10/10 0/13
Empiric antibiotic therapy 4/10 13/13










Invasive mechanical ventilation 1/10 4/13
AE-IPF acute exacerbation of idiopathic pulmonary fibrosis, rhTM recombinant
human soluble thrombomodulin, m-PSL pulse therapy intravenous
methylprednisolone 1 g/day for 3 days, rhTM therapy intravenous recombinant
human soluble thrombomodulin of 380 U/kg/day for 7 days
Table 4 Change in P/F ratio one week after treatment initiation
Day 1 Day 8
P/F ratio rhTM group 168 ± 56*,** 215 ± 88*,***
Untreated group 183 ± 47** 157 ± 55***
Data are expressed as the mean ± standard deviation
P/F ratio PaO2/FiO2 ratio
rhTM recombinant human soluble thrombomodulin
*The mean P/F ratio of the rhTM group on day8 was significantly higher than
on day1 (two-way ANOVA, p = 0.01)
**The difference between the group mean P/F ratios on day 1 was not
significant (two-way ANOVA, p = 0.5)
***The difference between the group mean P/F ratios on day 8 was not
significant (two-way ANOVA, p = 0.07)
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1 week after treatment initiation without any concomitant
use of cyclosporine or PMX and produced significantly
longer patients' survival than patients under historical
treatment. Thus, rhTM appears to be effective in the clin-
ical treatment of AE-IPF.
Recently, retrospective studies on the effects of rhTM
on AE-IPF were reported from 3 institutions in Japan,
with all studies reporting favorable effects for rhTM.
Tsushima et al. reported that the 28-day survival rate
was 65 % in 20 patients treated with rhTM and 17 % in
6 patients who were not treated with rhTM [16]. Like-
wise, Isshiki et al. reported that the 90-day survival rates
were 69 and 40 % in 16 patients treated with rhTM and
25 untreated patients, respectively [17], while Kataoka et
al. reported that the 90-day survival rates were 70 and
35 % in 20 patients treated with rhTM and in 20 control
patients, respectively [18].
There are some differences between the present study
and the 3 aforementioned studies. First, the sample size
in our study (10 patients in the rhTM group and 13 in
the untreated group) was smaller than that in the 3 previ-
ously reported studies. Furthermore, while the 3 studies
were conducted in a retrospective manner, our study
was conducted in a prospective manner according to a
previously published protocol (UMIN 000009082) that
included all patients with AE-IPF who provided in-
formed consent and who were registered after October
2012. In addition, there were some differences between
studies in the treatment methodologies utilized. Although
all studies, including ours, used steroid pulse therapy and
subsequent steroid administration, Kataoka et al. con-
comitantly administered cyclosporine to all 20 patients,
and Isshiki et al. administered cyclosporine to 15 of the 16
patients in their studies. The effectiveness of cyclosporine
for AE-IPF has already been demonstrated [19, 20], and
we also concomitantly used it to treat 6 of the 13 patients
in our untreated group. However, we prohibited the con-
comitant use of cyclosporine for the following reasons:
cyclosporine administration has not been accepted as a
standard therapy for AE-IPF yet. There are concerns re-
garding its considerable cost and adverse reactions, and
our goal was to assess the efficacy of rhTM alone. The
concomitant use of sivelestat sodium and PMX was also
prohibited in the rhTM group, although these drugs
were used to treat some patients in the untreated group
(Table 3).
It has been reported that NPPV shows certain efficacy
in AE-IPF [15, 21], but some investigators are against
the use of invasive mechanical ventilation. In our un-
treated group, none of the patients used NPPV, while 4
out of the 13 patients underwent endotracheal intubation,
all of whom died without being weaned from it. We
adopted a policy to not actively introduce endotracheal
intubation in the patients treated with rhTM, although we
Fig. 2 Serial changes in coagulation markers and HMGB1 levels of the patients in the rhTM group (n = 10). There were no significant changes
between the serial change in D-dimer, TAT, PIC and HMGB1 (one-way repeated ANOVA). Data are expressed as the group means ± standard deviation.
HMGB1: high mobility group box 1; TAT: thrombin-antithrombin complex; PIC: plasmin-α2 plasmin inhibitor complex. *n = 7, †n = 5
Fig. 3 Kaplan–Meier distribution for the probability of survival without
tracheal intubation. The solid line represents patients in the recombinant
human soluble thrombomodulin (rhTM) group, and the dotted line
represents patients in the untreated group. Survival was significantly
better in the rhTM group than in the untreated group at 1 year (p= 0.04,
log-rank test). rhTM: recombinant human soluble thrombomodulin
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introduced NPPV when the use of a Venturi mask could
not maintain an oxygen saturation of 90 % at FiO2 of
50 %. In addition, survival time was calculated using data
obtained from patients without endotracheal intubation to
avoid the potential influence of the life-extending effects
of endotracheal intubation on study results. In the rhTM
group, 1 patient each who underwent NPPV and endo-
tracheal intubation died within 28 days of the initiation of
rhTM therapy.
Collard et al. compared biomarker profiles between
patients with ALI and those with AE-IPF and reported
that protein C levels significantly decreased in the former
group but that levels remained within the normal range in
the latter group [8]. In the rhTM group patients in the
present study, protein C levels were also within the nor-
mal range before initiating rhTM treatment (Table 2). The
concentrations of D-dimer, TAT, and PIC were increased
before rhTM treatment, but all increases were moderate,
and only 2 patients met the Japanese diagnostic criteria
for acute DIC [22]. The concentrations of D-dimer, TAT,
and PIC tended to decrease with rhTM treatment, but the
differences were not statistically significant (Fig. 1).
On the other hand, Kataoka et al. reported that D-dimer
concentrations in bronchoalveolar lavage (BAL) fluid were
close to those in serum for patients with AE-IPF [18]. Be-
cause BAL fluid is a dilution of the alveolar lining fluid,
the D-dimer concentration in the alveolar lining fluid was
considerably higher than that in serum in their study.
Therefore, it is speculated that greater than expected co-
agulation abnormalities occur in regional lung tissues in
AE-IPF. Thus, it may be better to evaluate the concentra-
tions of coagulation markers in BAL fluid than in serum.
In the present study, the baseline concentration of
serum thrombomodulin did not exceed the normal range
in the 10 patients in the rhTM group (Table 2). Collard et
al. reported that serum thrombomodulin concentrations
were lower in patients with AE-IPF than in those with
ALI and suggested that low thrombomodulin is a poor
prognostic factor [8]. In addition, Ebina et al. reported
a decrease in thrombomodulin expression in autopsied
tissue from patients with AE-IPF [14]. Furthermore,
Ware et al. reported that thrombomodulin concentra-
tion in pulmonary edema fluid was higher than that in
the serum of patients with ALI/ARDS [23]. On the
other hand, Kataoka et al. reported that the concentra-
tion of thrombomodulin in BAL fluid was 10-fold lower
than that in serum in patients with AE-IPF. The same
study also showed that the D-dimer concentration in
BAL fluid was nearly equal to that in serum [18].
Therefore, it is assumed that the thrombomodulin con-
centration is relatively lower than the D-dimer con-
centration in the alveolar space. These findings suggest
that there is a relative deficiency of thrombomodulin in
the lung tissue and serum of patients with AE-IPF;
thus, supplementation with rhTM in these patients
should improve their condition.
Regarding the mechanism of action of rhTM, it was
reported to lower blood HMGB1 concentration. Ebina
et al. reported that the HMGB1 concentration in BAL
fluid increases in a time-dependent manner in patients
with AE-IPF [14]. Tsushima et al. also reported that the
serum HMGB1 concentration increases in a poor out-
come group but is unchanged in a good outcome group
[16]. However, marked changes in HMGB1 concentra-
tion were not observed in any patient in our study
(Fig. 2). It is necessary to clarify the time course change
in HMGB1 concentration in BAL fluid to verify whether
rhTM induces improvements in disease outcomes through
its regulation of HMGB1.
There are some limitations to this study. First, the study
was a single center, single arm, non-randomized clinical
study, though we used the historical untreated comparison
group. Second, the sample size was small, although signifi-
cant improvement was demonstrated even with this small
cohort, suggesting the excellent efficacy of rhTM. There
were, however, large variations in patients' background
factors before acute exacerbation, the data obtained
during acute exacerbation, and the changes in P/F ratio
after rhTM administration; clinical courses substantially
differed among patients. A larger scale study is required
to assess the efficacy of rhTM for treating various types
of patients. Third, we did not examine BAL fluid to
diagnose AE-IPF. The main purpose of BAL fluid examin-
ation was to eliminate the possibility of an active infection.
Instead of examining BAL fluid, we determined the pres-
ence or absence of an infectious disease by clinical exam-
ination, culture tests, antigen testing, antibody testing, and
procalcitonin level measurement. An antibacterial agent
was administered prior to rhTM treatment when infec-
tious disease was suspected, and rhTM treatment was
started only when the absence of an infection was con-
firmed. Antibacterial agents were given to 3 patients
whose symptoms did not improve after starting rhTM
plus steroid treatment, but their symptoms also did not
improve with antibacterial administration, and they subse-
quently died. Antibacterial agents were not administered
to the remaining 7 patients until they were discharged.
The possibility of an opportunistic infection was low in
the 10 rhTM subjects included in the analysis because
they did not receive any steroid or immunosuppressant
treatment and did not have poorly controlled diabetes.
Therefore, the possible involvement of a known infectious
disease was considered to be low in the disease conditions
of the patients with AE-IPF who received rhTM treatment.
However, as mentioned above, BAL fluid examination is
thought to be useful to assess coagulation and fibrinolytic
functions as well as to eliminate the possibility of infection.
Thus, examination of BAL fluid as well as measurement of
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coagulation and fibrinolytic markers in BAL fluid should be
performed when patient's conditions permit.
Conclusions
In conclusion, our findings showed that treatment with
rhTM and a steroid improves oxygenation in patients
with AE-IPF and is expected to improve their survival
without the use of other combination therapies. Larger
scale controlled trials are necessary to further demon-
strate the efficacy of rhTM in future patient populations.
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